Skip NavigationSkip to Content
Return Return to Search Results

Size matters: Superior Efficacy of Alpha Particle Radioimmunotherapy in Micrometastases versus Macrometastases

  1. Author:
    Patel, Ravi B [ORCID]
    Adler,Stephen [ORCID]
    Escorcia, Freddy E [ORCID]

  2. Author Address

    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States., Center for Cancer Research, Bethesda, MD, United States.,
    1. Year: 2025
    2. Date: May 14
    3. Epub Date: 2025 05 14
  2. Journal: Clinical Cancer Research : an official journal of the American Association for Cancer Research
  4. Type of Article: Article
  1. Abstract:

    Radiopharmaceuticals, which emit either alpha or beta particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted alpha-particle emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus to macrometastatic disease.

    See More

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.CCR-25-0654
  3. PMID: 40366383
  4. PII : 762425

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel